Experience with 5% ethanolamine oleate for sclerotherapy of oral vascular anomalies: A cohort of 15 consecutive patients.

Autor: Kato CNAO; Department of the Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil. Electronic address: cnao20@yahoo.com.br., Ribeiro MC; Department of Oral and Maxillofacial Surgery, Hospital Márcio Cunha, Ipatinga, Minas Gerais, Brazil., do Amaral MBF; Department of Oral and Maxillofacial Surgery, Hospital João XXIII/FHEMIG, Belo Horizonte, Brazil., Grossmann SMC; Department of Oral Pathology, Pontifical Catholic University of Minas Gerais (PUC Minas), Belo Horizonte, Minas Gerais, Brazil., de Aguiar MCF; Department of the Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil., Mesquita RA; Department of the Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.
Jazyk: angličtina
Zdroj: Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery [J Craniomaxillofac Surg] 2019 Jan; Vol. 47 (1), pp. 106-111. Date of Electronic Publication: 2018 Nov 16.
DOI: 10.1016/j.jcms.2018.11.009
Abstrakt: Purpose: To describe the effectiveness and safety of a sclerotherapy protocol with 5% ethanolamine oleate (EO) at 0.1 mL/3 mm for oral vascular anomalies (OVAs). Our hypothesis is that EO applied at a concentration of 5% may decrease the number of sessions necessary for clinical healing.
Materials and Methods: We describe a cohort of 15 consecutive patients. OVAs <20 mm were included. Clinical data of the OVAs were collected. Descriptive and bivariate statistical analyses were performed.
Results: Fifteen of the 19 OVAs were varicosities and the lower lip was the most affected site (n = 7). The median size was 6 mm, and one session was required in 89.5% of cases for clinical healing within 28 days. The pain/burning score was low (<2) for most lesions (63.1%) and the degree of satisfaction was high (>8) for all OVAs. The number of applications, final volume of drug and time to resolution differed significantly according to the size of the anomaly.
Conclusion: The protocol with 5% EO was shown to be effective and safe to treat OVAs <20 mm, and with a decrease in the number of sessions, volume and time to resolution, without complications and with high patient satisfaction.
(Copyright © 2018 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: